Poor
Not Aligned
Patient Risk:
Moderate
Summary
The response contains many claims marked absent from the supplied label excerpts, includes at least one potentially problematic adverse-effect sourcing/citation mismatch, and introduces several high-risk comparative potency and clinical positioning statements with no provided label support.
Category Scores
Accurate Statements
More serious side effects may include respiratory depression.
Supported by 5.2 Life-Threatening Respiratory Depression
More serious side effects may include serotonin syndrome, which is potentially life-threatening.
Supported by 5.9 Serotonin Syndrome Risk
More serious side effects may include dependence or addiction.
Supported by 5.1 Addiction, Abuse, and Misuse
Caution is advised for patients with a history of substance abuse.
Supported by 5.1 Addiction, Abuse, and Misuse
Tramadol hydrochloride is an opioid analgesic that works by altering the way the body perceives pain.
Partially supported by 12.1 Mechanism of Action (opioid activity mechanisms)
Tramadol works on the central nervous system by binding to opioid receptors, reducing transmission of pain signals to the brain.
Partially supported by 12.1 Mechanism of Action (mu-opioid receptor binding by parent/M1)
Tramadol affects serotonin and norepinephrine pathways to further modulate pain perception.
Partially supported by 12.1 Mechanism of Action (inhibition of reuptake of norepinephrine and serotonin)
Unsupported Statements
Paracetamol and tramadol hydrochloride tablets are a prescription medication used to manage moderate to moderately severe pain.
No label support provided for this indication framing in the supplied label excerpts; also label excerpts shown are for tramadol extended-release capsules.
Paracetamol (acetaminophen) is a non-opioid pain reliever and fever reducer.
No label support provided in the supplied label excerpts.
The combination provides a dual approach to pain relief.
No label support provided in the supplied label excerpts.
Paracetamol acts peripherally and centrally to inhibit prostaglandin synthesis involved in inflammatory and pain response.
No label support provided in the supplied label excerpts.
Doctors typically prescribe paracetamol and tramadol hydrochloride tablets for acute pain not adequately managed by non-opioid analgesics alone.
No label support provided in the supplied label excerpts.
This combination can be used for pain following surgery, dental procedures, or injuries.
No label support provided in the supplied label excerpts.
It is used for chronic pain conditions that require stronger pain management.
No label support provided in the supplied label excerpts.
Use for chronic pain may be limited due to potential for dependence and tolerance.
No label support provided in the supplied label excerpts for this specific limitation statement.
Common side effects of paracetamol and tramadol hydrochloride tablets include nausea, vomiting, constipation, dizziness, drowsiness, and headache.
Partially supported by mechanism excerpt for some symptoms, but the provided label citations list indicates a potentially incorrect sourcing (using 12.1 Mechanism of Action rather than a dedicated adverse reactions section).
More serious side effects can occur, particularly with higher doses or prolonged use.
Partially supported, but respiratory depression risk is explicitly tied to initiation/dose increase rather than generally ‘prolonged use’ in the cited excerpt.
Individuals with known hypersensitivity to tramadol or paracetamol, or to any inactive ingredients, should not take these tablets.
No contraindication/hypersensitivity language is supported by the supplied label excerpts.
Caution is advised for patients with respiratory conditions.
No direct label support provided for this ‘caution’ framing, despite respiratory depression guidance existing (5.2) that is not cited for this specific statement.
Patients should inform their doctor about other medications they are taking to avoid potentially dangerous interactions.
No label support provided in the supplied label excerpts.
Paracetamol and tramadol hydrochloride tablets are more potent than over-the-counter options like ibuprofen or naproxen.
No label support provided; comparative potency claims are not supported by supplied excerpts.
Paracetamol and tramadol hydrochloride tablets are less potent than stronger opioids such as morphine.
No label support provided; comparative potency claims are not supported by supplied excerpts.
The combination provides a step-up in pain management for moderate pain when simpler analgesics are insufficient.
No label support provided in the supplied label excerpts.
Compared to tramadol alone or paracetamol alone, the combination is often found to be more effective for a wider range of pain intensities.
No label support provided in the supplied label excerpts.
Prolonged use of paracetamol and tramadol hydrochloride tablets can lead to tolerance, where higher doses are needed to achieve the same pain relief.
No label support provided in the supplied label excerpts.
Prolonged use can lead to physical dependence, where withdrawal symptoms may occur if the medication is stopped abruptly.
No label support provided in the supplied label excerpts.
Long-term use requires careful medical supervision.
No label support provided in the supplied label excerpts.
Healthcare providers will typically aim to use the lowest effective dose for the shortest duration necessary.
No label support provided in the supplied label excerpts.
Contradictions
Important Omissions
Label-based contraindication/hypersensitivity details for the product (e.g., formal hypersensitivity contraindication or other contraindications) corresponding to the statement: ‘Individuals with known hypersensitivity... should not take these tablets.’
Importance:
High
Specific, label-supported drug interaction management (e.g., serotonergic drugs, CYP2D6/CYP3A4 inhibitors/inducers, MAOIs, CNS depressants) rather than general advice to inform the doctor.
Importance:
High
Label-aligned respiratory-risk guidance and timing (greatest during initiation or after dosage increase) connected to any respiratory-related warnings/cautions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several high-risk claims (comparative potency vs OTC/morphine, clinical use-case/indication positioning, and hypersensitivity contraindication framing) are not supported by the supplied label excerpts, and interaction-related counseling is not tied to specific label interaction warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple clinically important statements (indication/clinical use, hypersensitivity contraindication, respiratory and interaction guidance, comparative potency) lack support in the provided label excerpts and include at least one potentially problematic citation/sourcing issue for side effects.
Suggested Improvement
Restrict claims to statements directly supported by the supplied label excerpts (e.g., 12.1 mechanism; 5.1 addiction; 5.2 respiratory depression and timing; 5.9 serotonin syndrome; 5.16 GI contraindication specifics; and 7 drug interaction tables), remove unsupported comparative potency and product/indication framing, and ensure adverse-effect lists are sourced from the correct label sections.